Lusutrombopag

  • TRADE NAME: Mulpleta (Shionogi)
  • INDICATIONS: indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
  • CLASS: Thrombopoietin receptor (TPO) agonist
  • HALF-LIFE: ~27 hours

FDA APPROVAL DATE: 07/31/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
no available data to inform the drug-associated risk

Our database has 7 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CENTRAL NERVOUS SYSTEM
HEMATOLOGIC
OTHER


Page last updated 06/24/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top